EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?

J Thorac Oncol. 2018 Sep;13(9):1245-1247. doi: 10.1016/j.jtho.2018.06.009.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Carcinoma, Non-Small-Cell Lung*
  • ErbB Receptors
  • Erlotinib Hydrochloride
  • Humans
  • Lung Neoplasms*
  • Nivolumab
  • Protein Kinase Inhibitors

Substances

  • Protein Kinase Inhibitors
  • Nivolumab
  • Erlotinib Hydrochloride
  • EGFR protein, human
  • ErbB Receptors